JESSICA MANN: Open Payments
NPI 1336793751 · BATESVILLE, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,604 in 87 payments from 24 companies in 2025. Trend: 2023 $31 · 2024 $1,018 · 2025 $1,604
Food & beverage: $1,604
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. | 13 | $256 |
| Bayer Healthcare Pharmaceuticals Inc. | 12 | $209 |
| GlaxoSmithKline, LLC. | 10 | $170 |
| Novo Nordisk Inc | 9 | $145 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $93 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $85 |
| Xeris Pharmaceuticals, Inc. | 4 | $80 |
| Janssen Pharmaceuticals, Inc | 4 | $72 |
| AstraZeneca Pharmaceuticals LP | 3 | $65 |
Products named: IBSRELA, Kerendia, TRELEGY ELLIPTA, TRINTELLIX, CAPLYTA, XIFAXAN, Ozempic, SPRAVATO.
Industry payments across MS — which companies pay providers there.
